Drug-eluting Balloons in Coronary Artery Disease: Past, Present and Future

REVIEW, February 2012, VOL II ISSUE I, ISSN 2042-4884
10.5083/ejcm.20424884.69 , Cite or Link Using DOI
Creating a Digital Object Identifier Link

A digital object identifier (DOI) can be used to cite and link to electronic documents. A DOI is guaranteed never to change, so you can use it to link permanently to electronic documents.

To find a document using a DOI

  1. Copy the DOI of the document you want to open.
    The correct format for citing a DOI is as follows: doi:10.1016/S0140-6736(08)61345-8
  2. Open the following DOI site in your browser:
  3. Enter the entire DOI citation in the text box provided, and then click Go.
    The document that matches the DOI citation will display in your browser window.

The DOI scheme is administered by the International DOI Foundation. Many of the world's leading publishers have come together to build a DOI-based document linking scheme known as CrossRef.

Anouar Belkacemi, Pieter Stella, Michiel Voskuil, Kevin Onsea, Chunlai Shao, Pieter Doevendans, Pierfrancesco Agostoni

Percutaneous treatment of complex coronary lesions like small vessel disease, diabetics and long diffuse disease, remain hampered by suboptimal results, even with the use of drug-eluting stents (DES). The paclitaxel drug-eluting balloon (DEB) is an interesting emerging device to optimise the clinical outcomes in these specific lesions. In order to inhibit coronary restenosis, and revascular-isation, the DEB may become a viable alternative treatment option by means of a high concentration, local release of an anti-restenotic drug, paclitaxel, into the coronary vessel without using a metal scaffold or durable polymers.

Several studies have already shown promising and consistent results in the treatment of in-stent restenosis. Even when compared to certain DES, the DEB has demonstrated its added value. Inspired by these results, an increasing number of studies have been started in different coronary lesion subsets, exploring the value of the DEB in a broader range of lesions.

It will be interesting to see whether the DEB will find more indications beyond in-stent restenosis treatment. Moreover, as several DEB produced by different manufacturers, are present on the market, specific investigations are needed to address whether these devices offer the same added value, or show relevant differences.

As accounted for DES development in the past, now the puzzle pieces have to be put together for DEB.